Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07109245 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?

StatusRecruiting
PhasePhase 4
Started2025-12-11
View on ClinicalTrials.gov ↗

Amendment history

2026-03-30
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09-01→confirmed 2025-12-11
Study sitesdetails revised at 1 of 1 site
2025-07-31
minor
Original filing
This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose produced by the liver. After eating a meal, insulin levels go up in both the blood and the brain. Insulin in the brain has also been shown to affect the way the brain works and processes information (also known as "cognition"). Haloperidol, is an antipsychotic medication used to treat a variety of disorders such as schizophrenia spectrum disorders, bipolar disorder, and major depressive disorder, but long-term use can have metabolic side effects, like weight gain, type 2 diabetes, and cardiovascular disease. The purpose of this study is to investigate how antipsychotic medications, such as haloperidol, which carries the risk of metabolic changes, might interrupt the effect of insulin action in the brain. This will help researchers learn how to potentially reduce metabolic risk for people who take these kinds of medications in the future.
Trial Details
NCT Number NCT07109245
Lead Sponsor Centre for Addiction and Mental Health
Collaborators: The Physicians' Services Incorporated Foundation
Conditions Brain Insulin Sensitivity, Healthy Controls, Cognition
Enrollment 35 participants
Start Date 2025-12-11
Primary Completion 2028-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-02